- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| Fr | Mendus - CADENCE trial enrols first patient | 140 | Mendus has announced that the first patient has been enrolled in the CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG). This is a multi-centre, randomised, controlled... ► Artikel lesen | ||
| Fr | Pinewood (LSE: PINE) buys Seez | 166 | Pinewood has announced that it intends to acquire the remaining 90.9% stake in Seez for a total cost of $42m/£33.3m (Pinewood acquired an initial stake in Seez in September 2024 for $4.2m/£3.43m). Seez... ► Artikel lesen | ||
| Fr | Mendus (OMX: IMMU) notes first patient enrolment in the CADENCE trial | 162 | Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised... ► Artikel lesen | ||
| Do | IRLAB Therapeutics - EMA alignment on mesdopetam Phase III plans | 210 | IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European Medicines Agency (EMA) is aligned with the company... ► Artikel lesen | ||
| Do | Metlen (ASE: MYTIL) FY24 Results | 155 | Metlen's FY24 results released on 20 February were broadly in line with consensus (EBITDA €1,080bn, 0.9% above consensus of €1,070bn and 2.4% above Edison of €1055bn, EPS €4.46, 2.2% below consensus... ► Artikel lesen | ||
| Do | Mendus - Vididencel on track in AML going into 2025 | 160 | Mendus has reported its FY24 results, reflecting an active period. Lead programme, vididencel in acute myeloid leukaemia (AML), had encouraging data from the ADVANCE II trial in December, laying the... ► Artikel lesen | ||
| Do | Recce Pharmaceuticals - Positive R327G Phase II ABSSSI study results | 215 | Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial skin and skin structure infections (ABSSSI), including... ► Artikel lesen | ||
| Mi | Basilea Pharmaceutica - Another year, another market beat | 251 | Basilea recorded another strong year in FY24, its third successive year of cash flow positivity and its strongest operating performance to date. Lead drug Cresemba continued to dominate performance... ► Artikel lesen | ||
| Di | PZ Cussons - Less is more | 182 | PZ Cussons (PZC) is in transition. Both St Tropez (largely a US business) and Africa (mainly Nigeria) are potentially worth more to others than they are to PZC. Their disposal will reduce earnings volatility... ► Artikel lesen | ||
| Di | IRLAB Therapeutics - Financing improves operational flexibility | 116 | IRLAB Therapeutics has renegotiated its loan terms with Fenja Capital, allowing it to extend the duration of its SEK55m loan from 22 May 2025, potentially to 30 June 2026. The loan value may also be... ► Artikel lesen | ||
| Di | Molten Ventures - Investor day: Five strategic priorities outlined | 116 | During Molten Ventures' recent investor day, Ben Wilkinson (who was appointed CEO in October 2024 after serving as Molten's CFO for eight years) outlined the strategic priorities for the business. These... ► Artikel lesen | ||
| Di | The Diverse Income Trust - An exciting time for UK investors - enjoy the ride | 105 | The Diverse Income Trust's (DIVI's) portfolio is broadly diversified by sector and market cap, offering the potential for good upside in rising markets, and unlike the UK market, has consistently grown... ► Artikel lesen | ||
| Di | Dentsu Group - Mid-term management plan in place | 140 | Dentsu has published its FY24 results, which show a strong Q424 in its Japanese business, ensuring that the group effectively met November's net revenue guidance despite continuing weakness in international... ► Artikel lesen | ||
| Di | Lowland Investment Company - Dividends and buybacks rewarding patience | 189 | Lowland Investment Company's (LWI's) unconstrained, multi-cap investment policy differentiates it from most peers in the AIC UK Equity Income sector, offering investors broad market exposure outside... ► Artikel lesen | ||
| Di | Topps Tiles - Nearing resolution of CMA review | 196 | The announcement that the Competition and Markets Authority (CMA) has found Topps Tiles' (TPT's) acquisition of CTD Tiles generates no competition concerns in the majority of the areas reviewed should... ► Artikel lesen | ||
| Di | British American Tobacco - Moving to a smokeless world | 611 | British American Tobacco's (BAT's) strategy is to become a predominantly smokeless business, generating more than 50% of revenue (FY24: 17.5%) from smokeless products by FY35. The industry backdrop... ► Artikel lesen | ||
| Di | IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan | 202 | IRLAB has renegotiated its loan terms with FENJA Capital, allowing it to extend duration of the SEK55m loan from May 2025 to 31 December 2025 and potentially to 30 June 2026 (for an additional fee of... ► Artikel lesen | ||
| Mo | Theon International - Strong FY24 results; FY25 guidance confirmed | 216 | Theon has reported a strong set of maiden results as a listed company, along with good growth in order backlog, supporting positive guidance for FY25. Equally important are the operational milestones... ► Artikel lesen | ||
| Mo | GSK's (LSE: GSK) five-in-one vaccine approved by the FDA | 285 | GSK's five-in-one meningococcal vaccine, Penmenvy, has been approved by the US FDA for the treatment of meningitis, an indication that, in extreme cases, can lead to deadly brain swelling. More specifically... ► Artikel lesen | ||
| Mo | Topps Tiles (LSE:TPT) - CTD Tiles acquisition generated no competition concerns in majority of areas reviewed | 187 | Topps Tiles has announced the Competition and Markets Authority (CMA) found the proposed acquisition generated no competition concerns in the majority of areas reviewed. The CMA has identified possible... ► Artikel lesen | ||
| 14.02. | Knowit - Positive signs amid strong headwinds | 250 | Knowit reported signs of recovery at the end of a challenging 2024 that saw headcount reduced by 10%. Management has not only downsized the business but also taken steps to improve efficiency. This... ► Artikel lesen | ||
| 14.02. | Oryzon (BME: ORY) publishes REIMAGINE results in prestigious journal | 176 | Oryzon Genomics has announced the publication of the final Phase IIa REIMAGINE results in the journal Psychiatry and Clinical Neurosciences. The REIMAGINE trial evaluated the safety and efficacy of... ► Artikel lesen | ||
| 14.02. | Pinewood Technologies (LSE: PINE) signs significant new contract | 246 | Pinewood Technologies has signed a five-year contract with Global Auto Holdings (GAH) to implement the Pinewood Automotive Intelligence platform into all of its owned dealerships in the UK, North America... ► Artikel lesen | ||
| 13.02. | Actinogen Medical - XanaMIA Phase IIb/III study marches on | 200 | Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive mild-to-moderate Alzheimer's disease (AD). The company... ► Artikel lesen | ||
| 13.02. | Mendus - Focus firmly on pivotal-stage readiness in 2025 | 192 | Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
